Working towards its five-year strategy, the Royal Pharmaceutical Society (RPS) has put some plan in place to change its existing structure at the executive level, which could potentially render some senior positions redundant.
Though the process is in nascent stage, "two roles have been identified at potential risk of redundancy," RPS said in a statement on Thursday (March 3) afternoon, adding: "This is very much at proposal stage and no final decisions or outcomes have been reached."0
It didn't specify which two roles were going to be axed, saying: "We are unable to go into the specifics of the process for individuals due to its confidential nature, but we will of course go through a fair, reasonable and confidential consultation process and are supporting the individuals involved.
"No one should be in any doubt that our commitment to education and the profession's development remains the highest priority for us, and equally support for our members, thought leadership and advocacy are core to what we do as a professional leadership body."
The NHS is facing a range of long term challenges which needs to be countered with prevention, enhance personalised care and sustainable performance, health and social care secretary Sajid Javid said on Tuesday (March 8).
In his speech on healthcare reform at the Royal College of Physicians in London, he said: "We face some long-term challenges: how to keep the NHS focused on delivery while futureproofing it for changing demographics and disease; how to meet rising patient expectations and address the injustices of widespread disparities; and how to deal with an unsustainable financial trajectory while backing the brilliant people who work in health and care."
Javid emphasised on three key points for healthcare reform - prevention, personalisation and performance.
He said, prevention is not just about building a 'national hospital service' but a true 'National Health Service'.
While responding to the consultation on hub and spoke dispensing, trade unions for pharmacists have emphasised that the patient safety and care must be the priority in hub and spoke dispensing.
The Royal Pharmaceutical Society (RPS) has welcomed the opportunity provided by a change in legislation to enable community pharmacies to make use of hub and spoke
dispensing but reaffirmed that patient care must be at the heart of future changes.
With regards to patient safety, the Pharmaceutical Services Negotiating Committee (PSNC) considers that only Model 1 is appropriate, with manageable risks related
to patient safety, and is a model that has the potential to allow the whole sector to benefit fairly.
In its response to the consultation on Hub and Spoke dispensing, PSNC highlighted that Model 2 in the consultation, a hub direct to patient supply of dispensed medicines, raises patient safety issues and it cannot be supported.
RPS President Professor Claire Anderson said: "In all models, patients need to continue to have access to a pharmacist at the time of supply of medicines so they
have the opportunity to discuss, ask questions or raise concerns, and receive appropriate information with counselling and advice.
The Royal Pharmaceutical Society has appointed communications agency to lead a review into how it can develop and strengthen member participation.
"We've appointed communications consultancy Luther Pendragon to carry out an independent review of the participation of members and of our communications
concerning decisions we take on behalf of the profession through our Governance boards," the Society said in a statement on Tuesday (May 10).
It added that review would examine how RPS members, elected members and stakeholders can feel engaged, informed and empowered to influence decisions about RPS policy and understand why decisions around organisational policy have been taken on their behalf by elected representatives.
It will also ensure RPS decision-making processes are open and transparent with an emphasis on evidence-based decision making, and recommend ways elected members are enabled to be publicly accountable for decisions taken by the organisation at Board and Assembly level.
The Royal Pharmaceutical Society (RPS) has called its member to to express their views and fill out the Department of Health and Social Care's hub and
spoke survey on the proposed model of dispensing.
The Society has urged its members to fill out the survey before May 20.
RPS president Claire Anderson said: "It is vital that RPS members have their say on issue that impact you in your roles. Currently only single legal entities
can make use of this model of dispensing.
"Our survey, which opened today, seeks your views and comments and will help to inform the RPS submission to this consultation."
The consultation on the proposals to enable all community pharmacies to access hub and spoke dispensing published by the Department of Health and Social Care
(DHSC) will run for three months and will close on June 8, 2022.
Pharmacists with 'relevant experience in a pharmacy setting' can enroll for accredited independent prescribing course, as the General Pharmaceutical Council (GPhC) has decided to scrap the requirement of spending at least two years on the register and having previous experience in a specified clinical or therapeutic area before enrolling for the course.
The GPhC Council meeting held on Thursday instead proposed that applicants must have "relevant experience in a pharmacy setting and be able to recognise, understand
and articulate the skills and attributes required by a prescriber." This experience and awareness will act as the basis of their prescribing practice whilst training.
The regulator noted that the majority of stakeholder organisations, including the Chief Pharmaceutical Officers, the Royal Pharmaceutical Society and the statutory education bodies, were in favour of removing the requirement in a consultation on the topic.
They highlighted that a specific two-year period was not in itself a robust indication of whether an individual was ready to become a prescriber.
They also highlighted that the rapidly developing roles in the profession meant more pharmacists were likely to gain the necessary experience more quickly than in the past. A smaller number of organisations and a larger minority of individuals were opposed, citing that a specific two-year period gave pharmacists the time they needed to develop experience and confidence before being ready to enrol on a course.
The Royal Pharmaceutical Society (RPS) and Pharmacy Declares are inviting pharmacy teams from around the world to sign up and commit to taking "bold action"
on climate change as mentioned in a climate change charter which was published on Monday (June 13).
The charter asks pharmacy teams to commit to understanding how human health and the systems which underpin it are "reliant on the state of our natural environment"
and actively explore ways to make pharmacy practice and medicine use more sustainable.
It also asks to collaborate and share best practice to improve sustainability in pharmacy and healthcare; demonstrate leadership on sustainability or being a champion
for sustainability at work; and assist patients to optimise their medicine use to increase both health outcomes and environmental sustainability.
The individuals can also commit to a personal action on climate change of their own choosing.
The Charter is being supported by a strong coalition of organisations from across pharmacy including the Centre for Postgraduate Pharmacy Education, the Clinical
Pharmacy Association, College of Mental Health Pharmacy and Guild of Healthcare Pharmacists.
The General Pharmaceutical Council (GPhC) has removed a pharmacist from its register who black-marketed 'zolpidem' along with another pharmacist between 2015
and 2016.
Dean Zainool Dookhan, a pharmacist first registered with the Royal Pharmaceutical Society of Great Britain on 18 October 2004 and whose registration was later
transferred to the General Pharmaceutical Council under registration number 2059808, was jailed last year for exporting 20,000 packets of zolpidem to the Caribbean.
While hearing the case on 24-25 May, GPhC's Fitness to Practise Committee stated that "removal of the Registrant's name from the register is the appropriate and
proportionate response to his convictions."
"The public interest includes protecting the public, maintaining public confidence in the profession, and maintaining proper standards of behaviour. The Committee
is entitled to give greater weight to the public interest than the Registrant's own interest in remaining on the register."
"The Committee recognises the sanction has a punitive effect in that the Registrant's ability to practise and earn an income as a pharmacist and 28 his professional
reputation will be curtailed; it will be five years before he can seek restoration to the register. However, that is the price he must pay for failing to comply with the fundamental tenets of his profession."
The Royal Pharmaceutical Society (RPS) has published a new professional guidance for prescribing practice on Monday (June 6) which it says will be "for the
benefit of all independent prescribers across the UK".
Based on collaboration with multi-professional stakeholders, the document is a guidance tool for prescribers wanting to expand their prescribing scope of practice.
Commissioned by the Welsh government, the document was developed through an expert group with representatives from many healthcare professions, including from Higher Education institutions, professional bodies, regulatory bodies, the National Institute for Health and Care Excellence, NHS Education for Scotland, Health Education
and Improvement Wales, and representatives from hospital, community and GP practice.
RPS president Claire Anderson said: "It's fantastic to see the growth in prescribing, both across the profession and more widely, to improve patient care.
Prince Charles has praised the "dedication and professionalism of pharmacy staff" at an event held in London to celebrate the work of community pharmacists during the Covid-19 pandemic.
Two hundred pharmacists, pharmacy staff and other health service representatives were invited to attend a special reception hosted by His Royal Highness at St James's Palace on Wednesday night (May 4).
According to the National Pharmacy Association, the event was held, in part, to mark the NPA's recent centenary.
In his closing speech, The Prince of Wales paid tribute to the work of pharmacies on the NHS frontline.
He praised "the dedication and professionalism of pharmacy staff" during the Covid-19 pandemic and said: "I very much hope that this evening's event will help, a little bit, to highlight the marvellous work you do in your communities day in and day out."
The voter turnout in England for the Royal Pharmaceutical Society's English Pharmacy Board election dropped to 7.9 per cent this year.
Out of a total of 19,512 eligible individuals, only 1,534 decided to vote.
The RPS English Board received ten nominations for five vacancies this year; therefore an election was conducted. One nomination was received for the three
vacancies on the Welsh Pharmacy Board. Three nominations were received for the three vacancies on the Scottish Pharmacy Board. Therefore, no election was
conducted in pharmacy boards in Wales or Scotland.
RPS president Claire Anderson said: "It's disappointing that the voter turnout in England has dropped to 7.9 from 11.8 per cent in 2021. We have now appointed
an independent review of how RPS members, elected members and stakeholders can feel more engaged and empowered to influence RPS decisions, and eagerly await
its recommendations."
The Society appointed communications agency Luther Pendragon to lead a review into how it can develop and strengthen member participation.
Smoking increases the risk of developing schizophrenia and depression, a report by academics from the University of Bristol published on 20 June claims.
It says smoking raises the risk of developing schizophrenia by between 53 per cent and 127 per cent and the risk of developing depression by from 54 per cent to
132 per cent.
The authors of the report say more research is needed to identify why this is the case and that more evidence is needed to understand its impact on other mental
health conditions such as anxiety or bipolar disorder.
The evidence, presented at the Royal College of Psychiatrist's international congress, has been shared with the government which is currently developing a new
Tobacco Control Plan for publication later this year.
Action on Smoking and Health (ASH) said: "Rates of smoking are much higher among people with mental health conditions than those without, and among England's six
million smokers there are an estimated 230k smokers with severe mental illness (e.g., schizophrenia and bi-polar disorder) and 1.6 million with depression
and anxiety."
Ninety-six per cent of community pharmacists surveyed in the Royal Pharmaceutical Society (RPS) Workforce Wellbeing survey said they were at 'risk of burnout'.
A higher number of respondents working in community pharmacy (20%) reported not being offered breaks compared to all other sectors (8%) and were more likely to
experience verbal or physical abuse from patients and the public (69% vs an average 44%).
The annual Workforce Wellbeing survey also revealed that 88 per cent of pharmacists surveyed are at high risk of burnout due to winter pressure. Therefore, RPS is
calling for workforce planning for pharmacy to address skill mix and staffing levels so that workloads can be effectively managed.
Top factors causing poor mental health and wellbeing revealed by the survey include inadequate staffing (70%), lack of work/life balance (53%), lack of protected
learning time (48%) and lack of colleague/senior support (47%).
This is the fourth survey RPS has run in partnership with the charity Pharmacist Support on the state of mental health and wellbeing in pharmacy.
The findings demonstrate continued pressure on pharmacists and trainees across the workforce, especially in community pharmacy where 96% of those surveyed said they
were at risk of burnout.
Pharmacy leaders have called for reassurance that the workforce plan, expected by April 2023, will cover the entirety of the pharmacy workforce across the
health service, including in community pharmacies.
A joint letter has been signed by representatives from 14 pharmacy organisations which highlights that with continued pressures on services, it is more important
than ever to support the pharmacy workforce so that the staff needed to deliver patient care now and into the future can be recruited, trained and retained.
Mark Koziol, Pharmacists' Defence Association (PDA) Chairman said: "Our pharmacist members practise across the entire health system and have the potential to do far
more to help patients and improve public health, but they can only do so safely if they are in appropriately staffed workplaces. This is a workforce issue, so it is
important that the Government works with representatives of the pharmacist workforce, and of their employers, to get a suitably agreed plan in place."
Thorrun Govind, English Pharmacy Board Chair, Royal Pharmaceutical Society (RPS), said: "It will be crucial to use the skills of all our health professions to support
the NHS recovery, reduce health inequalities, manage the growing cost of long-term conditions, and deliver best value from medicines.
The result from the Royal Pharmaceutical Society (RPS)'s survey showed that pharmacists witnessed 'the cost of living is having an impact on whether people
can afford prescription medicines in England'.
RPS has long campaigned to remove prescription charges for people with long-term conditions in England because they create a financial barrier to patients receiving
the medicines needed to keep them well.
The charge currently stands at £9.35 per item prescrib9ed and an annual rise usually occurs in April. Prescriptions are free for people in Scotland, Wales and
Northern Ireland.
One in two pharmacists who responded to the survey said they've seen an increase in the last six months in patients asking them which medicines on their prescription
they can 'do without' due to affordability issues.
One in two pharmacists had seen a rise in people not collecting their prescription, whilst two out of three pharmacists reported an increase in being asked if there
was a cheaper, over-the-counter substitute for the medicine they had been prescribed.
The Royal Pharmaceutical Society (RPS) has backed a new framework from NHS England to reduce inappropriate prescribing of addiction-causing medicines.
It believes that the new framework is a positive step towards improving patient care by supporting medicine reviews and shared decision making to help people reduce
their use of medicines that are no longer providing much clinical benefit.
The society has also welcomed investment in innovative approaches to supporting patients and urged all pharmacists to refer people to such schemes.
Director for England at RPS, James Davies said: "Pharmacists are well-placed to help reduce inappropriate prescribing of high strength painkillers such as opioids
and other addictive medicines.
"Pharmacy teams can also often spot repeat purchases of over the counter medicines by patients so are well placed to intervene and give advice on the management of
chronic pain. Whilst opioids can play an important part in helping people with chronic pain there has long been a need for alternative approaches that are safer and
more effective for patients.
The National Pharmacy Association (NPA) and Royal Pharmaceutical Society (RPS) has been appointed as a core participant in the Covid-19 public inquiry.
The independent public inquiry has been set up to examine the UK's response to and the impact of the Covid-19 pandemic and learn lessons to shape preparations for
future pandemics. It is chaired by Baroness Heather Hallett, a former Court of Appeal judge.
The NPA and RPS will be part of Module 3, which covers the impact of Covid-19 on healthcare systems across the United Kingdom. The preliminary hearing for that
module takes place on Tuesday 28 February.
This will give the association an opportunity to make opening and closing statements, consider evidence provided to the Inquiry and propose questions to be asked by
the Inquiry of witnesses.
NPA chief executive, Mark Lyonette, said: "This is an historic opportunity to place on record the achievements of community pharmacy during the pandemic and to ensure
that the inquiry's recommendations are based in the practical realities faced by health workers such as our members.
The Royal Pharmaceutical Society (RPS) has confirmed that the recall of blood pressure drugs amlodipine and olmesartan by the Food and Drug Administration is
only for the US market and will not have any impact in the UK.
MHRA also clarified that the manufacturer of these drugs, Macleod Pharmaceuticals, does not supply amlodipine medicines in the UK.
It was published online in both the Daily Record and Daily Express on the morning of Monday, March 21, that the drugs had been recalled in the US by the FDA due to
deviations from standard manufacturing protocols by the manufacturer.
RPS intervened to ensure the articles were edited to make clear that this is not an issue in the UK after confirmation from the MHRA. Amlodipine tablets from Macleod
Pharmaceuticals aren't available for wholesale distribution in the UK.
The Royal Pharmaceutical Society (RPS) has called on employers, governments and NHS organisations to provide pharmacists with regular protected learning
time (PLT) within working hours to develop their skills in clinical delivery, education, research and leadership.
RPS workforce wellbeing survey showed an average 42 per cent of pharmacists were not given any PLT, a figure which rose to 55 per cent in community pharmacy. Most
were unable to engage in professional development activities as part of their working day because of their responsibility to deliver frontline clinical services to
patients.
This means learning is often undertaken outside of working hours, increasing pressure on individuals and impacting their work/life balance.
The survey showed that 48 per cent of respondents identified a lack of PLT as negatively affecting their mental health and wellbeing and that 88 per cent were at
high risk of burnout.
PLT improves the quality of patient care through professional practice and reflection, helping to develop insights, maintain and refine care standards and increase
confidence. It facilitates continuous professional development (CPD), ensuring that skills and knowledge are up to date.
The Royal Pharmaceutical Society (RPS) in collaboration with Health Education England's Centre for Advancing Practice and the Centre for Pharmacy Post
Graduate Education (CPPE) will provide a pharmacy-specific professional development pathway for advanced pharmacist practice.
Successful completion of the pathway, assured through the RPS Core Advanced Pharmacist Curriculum assessment, will result in pharmacists being recognised by RPS
as an advanced pharmacist, along with the awarding of HEE's Centre for Advancing Practice's 'Advanced' digital badge, demonstrating the quality assurance of their
advanced practice preparation to patients, families, carers, and other healthcare professionals.
The first participants in a fully funded, supported e-portfolio pathway to recognise advanced pharmacist practice in England will get underway in March 2023
This new programme is an important step in creating a clear postgraduate career structure for pharmacists in England.
The innovative approach provides funding from HEE's Centre for Advancing Practice in 2023-24 for 300 pharmacists in England who are near to, or already practicing at,
an advanced level, to enable them to receive supervision and support in building their RPS Core Advanced e-Portfolio from CPPE's pharmacy education supervisors.